It may be better to scramble our brains three ways instead of only one or two according to the latest research coming out of pharmaceutical companies. From The Wall Street Journal Health Blog:
For Antidepressants, Maybe Three Targets Will Be Better than Two
AstraZeneca said today that it’s partnering with the Mayo Clinic and Virginia Tech to work on an experimental class of antidepressants known as triple reuptake inhibitors, or TRIs.
DepressionThe drugs target three brain chemicals believed to be involved in depression — serotonin, norepinephrine and dopamine. Existing drugs target just serotonin, or serotonin and norepinephrine.
The project announced today has yet to test a TRI in people. That puts AstraZeneca a bit behind some other drug makers. In 2007, Danish firm NeuroSearch said it was carrying out a phase-2 study on a TRI with GlaxoSmithKline. Bristol-Myers Squibb has worked with Albany Molecular Research Inc. on similar drugs, and Dov Pharmaceutical said last year it was starting a phase-2 study on a TRI. (finish article here)
Our brave new world keeps on getting braver and braver. Oh the the new acronym on the block—TRI triple reuptake inhibitors. I’m sure it’s going to be hitting us from all sides very soon.